Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
Integra LifeSciences (Nasdaq:IART) has appointed Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings over 20 years of surgical and leadership experience from major MedTech companies, including Siemens Healthineers and Johnson & Johnson.
In his new role, Dr. Turner will lead worldwide medical affairs and clinical development activities, while maintaining his clinical practice. His extensive background includes serving as chief medical officer at Siemens Endovascular Robotics and program director at the Medical University of South Carolina. Dr. Turner has authored over 150 peer-reviewed publications and participated in more than 70 research studies.
Integra LifeSciences (Nasdaq:IART) ha nominato il dottor Raymond Turner come nuovo vicepresidente aziendale e chief medical officer. Il dottor Turner porta oltre 20 anni di esperienza chirurgica e di leadership presso importanti aziende MedTech, tra cui Siemens Healthineers e Johnson & Johnson.
Nel suo nuovo ruolo, il dottor Turner guiderà le attività mediche mondiali e lo sviluppo clinico, mantenendo la sua pratica clinica. Il suo vasto background comprende aver ricoperto il ruolo di chief medical officer presso Siemens Endovascular Robotics e program director presso la Medical University of South Carolina. Il dottor Turner ha pubblicato oltre 150 articoli sottoposti a peer review e ha partecipato a più di 70 studi di ricerca.
Integra LifeSciences (Nasdaq:IART) ha nombrado al Dr. Raymond Turner como nuevo vicepresidente corporativo y director médico. El Dr. Turner aporta más de 20 años de experiencia quirúrgica y de liderazgo en importantes empresas MedTech, incluyendo Siemens Healthineers y Johnson & Johnson.
En su nuevo cargo, el Dr. Turner dirigirá las actividades médicas mundiales y el desarrollo clínico, mientras mantiene su práctica clínica. Su amplia trayectoria incluye haber sido director médico en Siemens Endovascular Robotics y program director en la Medical University of South Carolina. El Dr. Turner ha escrito más de 150 publicaciones revisadas por pares y ha participado en más de 70 estudios de investigación.
Integra LifeSciences (나스닥: IART)가 새로운 기업 부사장 겸 최고의료책임자(CMO)로 레이몬드 터너 박사를 임명했습니다. 터너 박사는 시멘스 헬스키어스와 존슨 앤 존슨 등 주요 MedTech 기업에서 20년이 넘는 수술 및 리더십 경험을 보유하고 있습니다.
새로운 직책에서 터너 박사는 전세계 의료 업무 및 임상 개발 활동을 이끌면서도 임상 진료를 계속할 예정입니다. 그의 광범위한 배경에는 시멘스 엔도베스큘러 로보틱스의 최고의료책임자와 사우스캐롤라이나 의과대학의 프로그램 디렉터로 근무한 경험이 포함됩니다. 터너 박사는 150편이 넘는 동료심사(Peer-reviewed) 논문을 저술했고 70건이 넘는 연구 연구에 참여했습니다.
Integra LifeSciences (NYSE:IART) a nommé le Dr. Raymond Turner comme nouveau vice-président exécutif et directeur médical. Le Dr Turner apporte plus de 20 ans d'expérience chirurgicale et de leadership au sein de grandes entreprises MedTech, dont Siemens Healthineers et Johnson & Johnson.
Dans son nouveau rôle, le Dr Turner dirigera les activités médicales mondiales et le développement clinique, tout en poursuivant sa pratique clinique. Son parcours inclut des postes tels que directeur médical chez Siemens Endovascular Robotics et program director à l'University of South Carolina Medical. Le Dr Turner est l'auteur de plus de 150 publications évaluées par les pairs et a participé à plus de 70 études de recherche.
Integra LifeSciences (Nasdaq:IART) hat Dr. Raymond Turner als neuen Vice President of Corporate und Chief Medical Officer ernannt. Dr. Turner bringt über 20 Jahre chirurgische und Führungserfahrung von führenden MedTech-Unternehmen, darunter Siemens Healthineers und Johnson & Johnson, mit.
In seiner neuen Rolle wird Dr. Turner weltweite medizinische Angelegenheiten und klinische Entwicklungsaktivitäten leiten, während er seine klinische Praxis beibehält. Sein umfangreicher Hintergrund umfasst die Tätigkeit als Chief Medical Officer bei Siemens Endovascular Robotics und als Program Director an der Medical University of South Carolina. Dr. Turner hat über 150 peer-reviewed Veröffentlichungen verfasst und an über 70 Forschungsstudien teilgenommen.
Integra LifeSciences (ناسداك:IART) عينت الدكتور ريمون تيرنر كنائب رئيس الشركة ورئيسها الطبي الجديد. يجلب الدكتور تيرنر أكثر من 20 عامًا من الخبرة الجراحية والقيادية من شركات MedTech الكبرى، بما في ذلك Siemens Healthineers وJohnson & Johnson.
في دوره الجديد، سيقود الدكتور تيرنر شؤون الطب السريري والتطوير الطبي العالمي، مع الحفاظ على ممارسته السريرية. يشمل خلفيته الواسعة العمل كـ كبير مسؤولي الطب (CMO) في Siemens Endovascular Robotics و< b>مدير البرنامج في Medical University of South Carolina. الدكتور تيرنر مؤلف أكثر من 150 منشورًا خاضعًا للمراجعة من الأقران وشارك في أكثر من 70 دراسة بحثية.
Integra LifeSciences (纳斯达克代码:IART) 已任命 雷蒙德·特纳博士 为新的公司副总裁兼首席医疗官。特纳博士带来了来自包括西门子健康护理与强生在内的主要医疗科技公司在内的 超过20年的外科与领导经验。
在新任命的职位上，特纳博士将领导全球医疗事务和临床开发活动，同时维持他的临床执业。他的丰富背景包括担任 西门子血管内机器人公司的首席医疗官 以及南卡罗来纳医科大学的 项目主任。特纳博士已撰写 超过150篇同行评议论文，并参与了 超过70项研究。
- Appointment of highly qualified CMO with over 20 years of surgical and leadership experience
- New CMO brings extensive research background with 150+ publications and 70+ research studies
- Dual role maintaining clinical practice while serving as CMO provides ongoing practical insights
- Strong industry experience from leadership roles at Siemens Healthineers and Johnson & Johnson
- None.
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.
Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world’s largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providing patients with neurosurgical care.
“Dr. Turner’s extensive medical and clinical experience and expertise will be significant assets to Integra as we strengthen our focus on building robust clinical evidence,” said Mojdeh Poul, president and chief executive officer, Integra LifeSciences. “His proven leadership and passion for advancing safety and quality will help us continue to deliver innovative solutions and transform patient care for the millions around the world.”
Prior to joining Integra, Dr. Turner held various leadership roles at Siemens Healthineers, including his most recent position as the chief medical officer for Siemens Endovascular Robotics. Prior to this, he was a medical director for Cerenovus, a Johnson & Johnson MedTech company. Additionally, Dr. Turner served as the program director of the neurosurgery residency program and was the chief of neuroscience (neurological surgery, neurology, and ENT) at the Medical University of South Carolina.
“I am excited to be joining Integra, an organization deeply committed to providing best-in-class, evidence-based products that help restore patient lives,” said Dr. Raymond Turner. “I look forward to working closely with both the Integra team and our healthcare partners to improve patient outcomes and uphold the highest standards of care.”
Dr. Turner served as a practicing surgeon at PRISMA Health and most recently, at Intermountain Health in Billings, Montana. He currently serves as an examiner for the American Board of Neurological Surgery.
Dr. Turner completed his undergraduate degree in biology at Sacred Heart University in Connecticut. He obtained his medical degree at Karol Marcinkowski University of Medical Sciences in Poznan, Poland. Dr. Turner completed his residency in neurological surgery and his fellowship in endovascular neurosurgery at the Cleveland Clinic. He has authored more than 150 peer-reviewed publications and has been involved in more than 70 pre-clinical and clinical research studies.
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1bd1b51-a9bb-4545-b463-a79108abf93f
FAQ
Who is the new Chief Medical Officer of Integra LifeSciences (IART)?
What will be Dr. Turner's responsibilities at Integra LifeSciences (IART)?
What is Dr. Raymond Turner's background before joining Integra (IART)?
Where did Dr. Turner complete his medical education and training?
How will Dr. Turner's appointment impact Integra LifeSciences (IART)?
